Takeda's Phase III Dengue Vaccine Results Bring Them "One Step Closer" to Stopping Tropical Disease

Takeda Pharmaceutical announced that its vaccine for dengue fever hit its primary efficacy endpoint in its Phase III clinical trial. Dengue fever affects as many as 400 million people annually, according to the U.S. Centers for Disease Control and Prevention (CDC). It is caused by one of four related viruses transmitted by mosquitoes. Symptoms usually start four to seven days after the mosquito bite and usually last three to 10 days. About 2.5 billion people
Read more...

;